The No. 1* recommendation for non-melanoma skin cancer** Eryfotona® AK Fluid is a medical device for the prevention and supportive treatment of actinic keratoses and non-melanoma skin cancer (NMSC). Eryfotona® AK Fluid offers very high sun protection SPF 50+ combined with a DNA repair enzyme (photolyase). This sunscreen prevents damage caused by sun exposure and supports the treatment of skin changes. What makes this product special is that unique Repairsomes® form a protective film on the skin, reducing the formation of new lesions. With visible results after 3 months of treatment(2) Regular use of sunscreen with a very high sun protection factor (SPF 50+) supports the natural DNA repair mechanism. This reduces DNA damage caused by sun rays by half, thus decreasing the likelihood of new lesions appearing after photodynamic therapy.(4) The photolyase contained in Eryfotona® AK repairs DNA(3) Sunlight attacks skin cells and damages DNA. Healthy people can naturally repair 45% of this sun damage. Eryfotona® AK Sunscreen for light-colored skin cancer** exclusively contains DNA Repairsomes®, an ISDIN-patented technology that supports the body in repairing an additional 45% of this DNA damage. This effectively doubles the skins ability to repair itself. The texture of the facial sunscreen becomes more fluid when shaken and melts into the skin. This facial sunscreen with a very high sun protection factor absorbs quickly and leaves a pleasant feeling on the skin. Suitable for all skin types. *Based on the number of green prescriptions in the ATC3 (D02O sunscreen) market at pharmacies. As of MAT 08/2023, Pharmacy Sell-Out INSIGHT Health. **non-melanocytic (2) Phototype II with multiple lesions treated with AK-NMSC eryphoton twice daily over the entire cancer area. (3) Stege H. et al. Enzymes plus light therapy to repair DNA damage in ultraviolet biradiated human skin. Proc Natl Acad Sci USA, 2000; 97(4): 1790-5. (4) Piaserico S. Cancerization field treatment with topical photolyase improves clinical outcomes after photodynamic therapy in patients with actinic keratosis: A prospective randomized intra-patient controlled pilot study. Sidemast 2012.8. Application: For non-melanoma skin cancer, apply sunscreen generously twice daily, morning and midday, to the entire affected area and other vulnerable, sun-exposed areas (face, forehead, ears, décolleté, bald head, and backs of hands). The photolyase effect is activated by visible light. For facial care in cases of actinic keratosis, the use of Eryfotona Night is recommended for overnight skin regeneration.